Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.

Bosbach B, Deshpande S, Rossi F, Shieh JH, Sommer G, de Stanchina E, Veach DR, Scandura JM, Manova-Todorova K, Moore MA, Antonescu CR, Besmer P.

Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):E2276-83. doi: 10.1073/pnas.1115240109. Epub 2012 May 31.

2.

Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.

Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR.

Clin Cancer Res. 2007 Aug 15;13(16):4874-81.

3.

KIT receptor gain-of-function in hematopoiesis enhances stem cell self-renewal and promotes progenitor cell expansion.

Deshpande S, Bosbach B, Yozgat Y, Park CY, Moore MA, Besmer P.

Stem Cells. 2013 Aug;31(8):1683-95. doi: 10.1002/stem.1419.

4.

Resistance to c-KIT kinase inhibitors conferred by V654A mutation.

Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, Lyons AB, Ashman LK.

Mol Cancer Ther. 2007 Mar;6(3):1159-66.

5.

Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.

Bardsley MR, Horváth VJ, Asuzu DT, Lorincz A, Redelman D, Hayashi Y, Popko LN, Young DL, Lomberk GA, Urrutia RA, Farrugia G, Rubin BP, Ordog T.

Gastroenterology. 2010 Sep;139(3):942-52. doi: 10.1053/j.gastro.2010.05.083. Epub 2010 Jun 4.

6.

Gastrointestinal stromal tumors.

Antonescu C.

Curr Top Microbiol Immunol. 2012;355:41-57. doi: 10.1007/82_2011_161. Review.

PMID:
22015552
7.

[The importance of mutational status in prognosis and therapy of GIST].

Comandone A, Boglione A.

Recenti Prog Med. 2015 Jan;106(1):17-22. doi: 10.1701/1740.18950. Italian.

PMID:
25621775
8.

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M.

Clin Cancer Res. 2006 Apr 15;12(8):2622-7.

9.
10.

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.

Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A, Marynen P.

Gastroenterology. 2005 Feb;128(2):270-9.

PMID:
15685537
11.

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J, Wardwell S, Ning Y, Song Y, Kohlmann A, Wang F, Clackson T, Heinrich MC, Fletcher JA, Bauer S, Rivera VM.

Clin Cancer Res. 2014 Nov 15;20(22):5745-55. doi: 10.1158/1078-0432.CCR-14-1397. Epub 2014 Sep 19.

12.

Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.

Rossi F, Yozgat Y, de Stanchina E, Veach D, Clarkson B, Manova K, Giancotti FG, Antonescu CR, Besmer P.

Mol Cancer Res. 2010 Sep;8(9):1271-83. doi: 10.1158/1541-7786.MCR-10-0065. Epub 2010 Aug 24.

13.

Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503.

Liu NN, Ohkouchi M, Hashikura Y, Kajimoto N, Matsuda I, Isozaki K, Toh Y, Takahashi T, Nishida T, Hirota S.

Lab Invest. 2013 May;93(5):502-7. doi: 10.1038/labinvest.2013.43. Epub 2013 Mar 4.

14.

Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.

Heinrich MC, Marino-Enriquez A, Presnell A, Donsky RS, Griffith DJ, McKinley A, Patterson J, Taguchi T, Liang CW, Fletcher JA.

Mol Cancer Ther. 2012 Aug;11(8):1770-80. doi: 10.1158/1535-7163.MCT-12-0223. Epub 2012 Jun 4.

15.

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.

Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle R, Bearss D.

Oncogene. 2007 Jun 7;26(27):3909-19. Epub 2007 Feb 26.

PMID:
17325667
16.

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.

Edris B, Willingham SB, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Montgomery KD, Contreras-Trujillo H, Czechowicz A, Fletcher JA, West RB, Weissman IL, van de Rijn M.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3501-6. doi: 10.1073/pnas.1222893110. Epub 2013 Feb 4.

17.

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.

Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, Besmer P, Antonescu CR.

Genes Chromosomes Cancer. 2008 Oct;47(10):853-9. doi: 10.1002/gcc.20589.

18.

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.

Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP.

Clin Cancer Res. 2005 Jun 1;11(11):4182-90.

19.

Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.

Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD, Maki RG, Singer S, Dematteo RP, Besmer P, Antonescu CR.

Clin Cancer Res. 2009 Nov 15;15(22):6862-70. doi: 10.1158/1078-0432.CCR-09-1315. Epub 2009 Oct 27.

20.

Molecular research directions in the management of gastrointestinal stromal tumors.

Tarn C, Godwin AK.

Curr Treat Options Oncol. 2005 Nov;6(6):473-86. Review.

PMID:
16242052
Items per page

Supplemental Content

Write to the Help Desk